Shares of Oddity Tech (ODD) have gained 7.2% over the past four weeks to close the last trading session at $42.4, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $66.82 indicates a potential upside of 57.6%.The mean estimate comprises 11 short-term price targets with a standard deviation of $12.63. While the lowest estimate of $46.00 indicates an 8.5% increase from the current p ...

Shares of Klarna (KLAR) have gained 8.4% over the past four weeks to close the last trading session at $30.48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $46.06 indicates a potential upside of 51.1%.The mean estimate comprises 16 short-term price targets with a standard deviation of $3.7. While the lowest estimate of $39.00 indicates a 28% increase from the current price le ...

Nuvation Bio Inc. (NUVB) closed the last trading session at $8.99, gaining 28.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $11.25 indicates a 25.1% upside potential.The average comprises eight short-term price targets ranging from a low of $8.00 to a high of $18.00, with a standard deviation of $2.96. While the lowest estimate indicates a decline of 11% from the current price ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

If you haven't thought about diversifying your equity portfolio internationally, perhaps the performance of non-U.S. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...